OBJECTIVE: We conducted a population-based pharmacokinetic study to assess blood levels and elimination of mercury after vaccination of premature infants born at > or =32 and <37 weeks of gestation and with birth weight > or =2000 but <3000 g. STUDY DESIGN:Blood, stool, and urine samples were obtained before vaccination and 12 hours to 30 days after vaccination from 72 premature newborn infants. Total mercury levels were measured by atomic absorption. RESULTS: The mean +/- standard deviation (SD) birth weight was 2.4 +/- 0.3 kg for the study population. Maximal mean +/- SD blood mercury level was 3.6 +/- 2.1 ng/mL, occurring at 1 day after vaccination; maximal mean +/- SD stool mercury level was 35.4 +/- 38.0 ng/g, occurring on day 5 after vaccination; and urine mercury levels were mostly nondetectable. The blood mercury half-life was calculated to be 6.3 (95% CI, 3.85 to 8.77) days, and mercury levels returned to prevaccination levels by day 30. CONCLUSIONS: The blood half-life of intramuscular ethyl mercury from thimerosal in vaccines given to premature infants is substantially shorter than that of oral methyl mercury in adults. Because of the differing pharmacokinetics, exposure guidelines based on oral methyl mercury in adults may not be accurate for children who receive thimerosal-containing vaccines.
RCT Entities:
OBJECTIVE: We conducted a population-based pharmacokinetic study to assess blood levels and elimination of mercury after vaccination of premature infants born at > or =32 and <37 weeks of gestation and with birth weight > or =2000 but <3000 g. STUDY DESIGN: Blood, stool, and urine samples were obtained before vaccination and 12 hours to 30 days after vaccination from 72 premature newborn infants. Total mercury levels were measured by atomic absorption. RESULTS: The mean +/- standard deviation (SD) birth weight was 2.4 +/- 0.3 kg for the study population. Maximal mean +/- SD blood mercury level was 3.6 +/- 2.1 ng/mL, occurring at 1 day after vaccination; maximal mean +/- SD stool mercury level was 35.4 +/- 38.0 ng/g, occurring on day 5 after vaccination; and urine mercury levels were mostly nondetectable. The blood mercury half-life was calculated to be 6.3 (95% CI, 3.85 to 8.77) days, and mercury levels returned to prevaccination levels by day 30. CONCLUSIONS: The blood half-life of intramuscular ethyl mercury from thimerosal in vaccines given to premature infants is substantially shorter than that of oral methyl mercury in adults. Because of the differing pharmacokinetics, exposure guidelines based on oral methyl mercury in adults may not be accurate for children who receive thimerosal-containing vaccines.
Authors: F Bakir; S F Damluji; L Amin-Zaki; M Murtadha; A Khalidi; N Y al-Rawi; S Tikriti; H I Dahahir; T W Clarkson; J C Smith; R A Doherty Journal: Science Date: 1973-07-20 Impact factor: 47.728
Authors: Brian J Anderson; Richard A van Lingen; Tom G Hansen; Yuan-Chi Lin; Nicholas H G Holford Journal: Anesthesiology Date: 2002-06 Impact factor: 7.892
Authors: George Curlin; Sarah Landry; Jessica Bernstein; Richard L Gorman; Barbara Mulach; Charles J Hackett; Stephanie Foster; Sarah E Miers; Patricia Strickler-Dinglasan Journal: Pediatrics Date: 2011-04-18 Impact factor: 7.124
Authors: Karola Jering; Michael Aschner; Amy Beller; Ellyn L Hamm; Margaret Langdon; Nathalie L Maitre Journal: J Pediatr Date: 2015-03-24 Impact factor: 4.406
Authors: David A Geier; Janet K Kern; Brian S Hooker; Paul G King; Lisa K Sykes; Kristin G Homme; Mark R Geier Journal: Interdiscip Toxicol Date: 2015-06
Authors: David A Geier; Brian S Hooker; Janet K Kern; Paul G King; Lisa K Sykes; Mark R Geier Journal: Int J Environ Res Public Health Date: 2014-09-05 Impact factor: 3.390